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Background: Host genetic factors that may confer a susceptibility to chronic hepatitis and the progression
of hepatocellular carcinoma (HCC) are largely unknown. Apoptosis is an important fail-safe check for the
hepatitis virus and HCC development, in which Fas/FasL hepatocyte expression contributes substantially.
Aim: To determine whether the Fas/FasL gene promoter polymorphism at Fas-670, Fas-1377 and Fas-L844
are associated with the risk of virus hepatitis or the prognosis of HCC patients.
Patients and methods: We conducted a retrospective hospital-based caseecontrol study in which 142
HCC patients were enrolled. The study patients were divided into three groups: 1) hepatitis B with
Lamivudine treatment (N ¼ 107), 2) hepatitis C with interferon treatment (N ¼ 50), and 3) a non-HCC
control group of patients (N ¼ 300). Of the 142 total enrolled patients from the ﬁrst two groups, 110
underwent liver resection. There were 59 patients with early recurrence (<1 year post operation),
31 patients with late stage HCC (CLIP score 2e6), and 22 patients with AFP >400 ng/ml. All of the
patients in these groups were tested for Fas/FasL polymorphism by PCR-RFLP. The frequency of allele
and genotype were compared between each group. The signiﬁcant SNP (single nucleotide poly-
morphism) correlated with patient clinical characteristics and was a surrogate for recurrence or
survival analysis.
Results: In the control group, the C/T ratio in FasL was 71.4/28.6, the A/G ratio in Fas670 was 55.28/44.7,
and the A/G ratio in Fas1377 was 41.3/58.7. There were no signiﬁcant differences between these numbers
and similar numbers in the HCC, HBV, HCV or surgical group. In the genotype pattern of Fas670, the A/A
to A/G þ G/G ratio was 30.3/69.7 and they are signiﬁcant to the HCV hepatitis group 16.0/84.0 (the P
value ¼ 0.026). In Fas1377, the A/A þ A/G to G/G ratio was 66.7/33.3 and they are signiﬁcant to the HCV
hepatitis group 84.0/16.0 (p < 0.01). Comparing the surgical HCC group of early stage (CLIP score 0e1)
and late stage HCC (CLIP score 2e6), C/C to T/C þ T/T ratios are signiﬁcant (p < 0.01) in the genotype of
FasL. Comparing the surgical HCC group of AFP <400 ng/ml and >400 ng/ml, C/C to T/C þ T/T ratios are
signiﬁcant (p < 0.01) in the genotype of FasL. There was no difference in the overall 10-year survival or
recurrence rate between FasL genotype C/C and T/C þ T/T., Department of Surgery, National Defense Medical Center, Tri-Service General Hospital, No 325, Sec. 2, Cheng-Kung Rd,
ackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd. Taipei City, Taiwan.
sieh), liutp@mmh.org.tw (T.-P. Liu).
ncology Society.
Society. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
G.-S. Liao et al. / Journal of Cancer Research and Practice 3 (2016) 9e1310Conclusions: The apoptosis mechanism of Fas/FasL interaction may contribute to HCV-related hepatitis
and the late stage (CLIP score 2e6) of the surgical HCC group. The genetic polymorphisms of Fas1377
could play a role in the process of hepatitis C virus infection transforming to liver cirrhosis. Additionally,
our research suggests that there may be a correlation between the genetic polymorphisms of FasL in HCC
patients, and patient prognosis based upon serum AFP levels.
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Epidemiological studies have shown that viral infections such as
hepatitis C virus (HCV) and hepatitis B virus (HBV) are important
factors contributing to hepatocellular carcinoma (HCC) develop-
ment. Chronic HCV leads to cirrhosis in approximately 20% of pa-
tients over a 10e20 year period, and approximately 10e20% of
cirrhotic patients will develop HCC within 5 years.1,2 Viral hepatitis
is a major etiological agent of chronic hepatitis, cirrhosis and he-
patocellular carcinoma. Fas-mediated apoptosis is the major cause
of hepatocyte damage during liver disease.3 Although molecular
events of HCC carcinogenesis have been studied extensively, the
mechanism remains largely elusive. In patients with HBV infection,
the HBx gene encodes a protein called HBV X protein1 and its
interactionwith proteasome subunits might be responsible for HCC
carcinogenesis.2 In patients infected with HCV, the mechanisms
causing viral evasion of cell-mediated immune responses leading to
apoptotic death of hepatocytes might contribute to viral persis-
tence. Such amechanismmight also contribute to the development
of liver cancer.4 Progressive liver damage from viral hepatitis may
be the results of repeated attempts by cytotoxic T lymphocytes
(CTL) to clear infected hepatocytes.5 Histological necroin-
ﬂammation is a well-recognized phenomenon in chronic HCV
infection. Reports have shown that altered regulation of apoptosis
was associated with the pathogenesis of HCC and dysplasia,6 pri-
mary biliary cirrhosis,7 viral hepatitis1e4 and liver disease induced
by ethanol,8 bile salts,9 toxins and drugs.10 Indeed, both HBxAg and
the HCV core protein have been reported to induce the expression
of FasL on HCC cells, which counter-attack CTL for immune
evasion.11,12
Fas/FasL, a transmembrane receptor, is a member of the tumor
necrosis factor receptor superfamily, which play an important role
in embryogenesis, autoimmunity, liver cirrhosis and tumorigen-
esis.3,4 Engagement of the Fas ligand (FasL) triggers programmed
cell death, which is important in apoptosis mediated by cytotoxic T
lymphocytes (CTL) and natural killer (NK) cells.13
Genetic polymorphisms with functional differences of Fas/FasL
genes were recently reported to be associated with autoimmune
diseases including cervix cancer,14 HCV related liver cirrhosis,15,16
lung cancer,17 and esophageal cancer.18 The present study was
intended to test the hypothesis that genetic polymorphisms of Fas/
FasL promoter may be associated with individual susceptibility to
virus hepatitis, and the prognosis of HCC in a Taiwanese population.2. Materials and methods
2.1. Patients
A retrospective hospital-based caseecontrol study was con-
ducted. The study cases included 157 liver cirrhosis patients
without HCC undergoing antivirus treatment, and 142 HCC pa-
tients, all of which were diagnosed and treated at the Tri-Service
General Hospital, Taipei, Taiwan, between 1999 and 2003. The
latest follow-up for these patients was June 1st, 2013. The antivirustreatment protocol was according to the guidelines of the Bureau of
National Health Insurance in Taiwan. All patients were assessed for
general characteristics, laboratory data, treatment modalities, and
prognosis. Therewere 142 patients with HCC recruited out of which
100 and 35 patients were found to be positive for HBV and HCV
infection, respectively. From the 142 patients with HCC, 110 un-
derwent liver resection. All of the surgical HCC patients were
assessed for clinical characteristics, laboratory data, liver function
status, pathology report, tumor size and pattern, viral hepatitis
status, CLIP stage,19 Child-Pugh score, recurrence time, and survival
follow-up. In the cirrhotic patients, 107 patients were HBsAg serum
positive with symptoms with lamivudine treatment and 50 pa-
tients were anti-HCV antibody positive with symptoms with
interferon therapy. Patients that were infected with both HBV and
HCV were excluded from the cirrhotic group.
Age matched (N ¼ 300) controls were enrolled, where volun-
teers attending their routine physical check-up agreed to partici-
pate and provided informed consents. Exclusion criteria included
any history of immune-compromised conditions or chronic or
acute viral infections and other cancers. All the patients were
investigated and managed under the standard protocol at the same
hospital. The study was approved by the Institute Review Board of
Ethics of the Tri-Service General Hospital.2.2. Determination of Fas/FasL promoter polymorphisms
Whole blood from patients and controls were extracted for DNA
by using QIAGEN DNA extraction kits (QIAGEN, Dusseldorf, Ger-
many) following the manufacturer's protocol. The genomic DNA
concentration was determined by using ﬂuorescent illumination
with PicoGreen dye (Molecular Probes, OR). Polymorphisms were
determined using TaqMan probes as previously described.14 In
brief, ﬂuorescence-labeled allele-speciﬁc probes were used: FAS-
670A/G, 50-FAM-CATTCCAGAAACGTC-30 and 50-VIC-CATTCCAGGAA
CGTC-3’; FAS -1377G/A, 50-FAM-AAGACCCTGGGTGTGCCAGCCT-30
and 50-VIC-CCCTGGGCGTGCCAGCCT-3ʹ; FASL-844 C/T, 50-FAM-
CTTTGTATTTCACAATGTT-30 and 50-VIC-TTTGTATTTCGCAATGTT-3ʹ.
PCR oligonucleotide primers spanning the FAS-670 polymorphism
were 50CTATGGCGCAACATCTGTACTTTT-3ʹ (forward) and 50-GTC
CATGTTGTGGCTGCAA-3ʹ (reverse). Primers spanning the FAS-1377
polymorphism were 50-CTATTAGATGCTCAGAGTGTGTGCA-3ʹ (for-
ward) and 50GCTTGTCTCTGTTCCACCTTTCA-3ʹ (reverse). Primers
spanning the FASL-844 polymorphism were 50-CCTGGGTGACA-
GAGTGAGACT-3ʹ (forward) and 50-AGGCTGCAAACCAGTGGAA-3ʹ
(reverse). Standard TaqMan cycling conditions were used (40 cycles
at an annealing temperature of 60-C) for real-time PCR with an ABI
7700 (Applied Biosystems, Foster City, CA, USA). The genotypes
were determined by the endpoint products. The polymorphic se-
quences of ten randomly selected samples were determined for
each SNP by using DNA sequencing (CEQ8000, Beckman Coulter,
Fullerton, CA, USA).
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The difference inmean ages between the HCC cases and controls
were examined using Student's t-test. Associations of Fas/FasL ge-
notype and allele frequencies with control, HCC and virus-related
hepatitis were analyzed by use of the c2 test and Fisher's exact
test as necessary. Survival probabilities were calculated using the
KaplaneMeier method and compared using the log-rank test. Cox
proportional hazard function model was used to test the inde-
pendent prediction of prognosis. For all statistical tests, the level of
signiﬁcance was set at 0.05.
3. Result
The gender distributions (M/F) in the cirrhosis group and the
HCC group were 106/51 and 100/42, respectively. Overall, therewas
no real difference between these distributions and the control
group (200/100). The clinical characteristics were summarized in
Table 1. The mean patient age in the cirrhotic group was 59.3 ± 13.4
years, and in the HCC group was 58.9 ± 13.3 years; similarly, there
was no difference from the control group's mean patient age. There
were 107 patients of the cirrhotic group that had a history of HBV
infection, and 50 patients with a history of HCV infection. In the
HCC group, there were 100 patients with HBV infection and 35
patients with HCV infection, again showing little difference in
distribution between the two groups. One of the exclusion criteria
for the control group was hepatitis virus infection, so all patients in
the control group had no history of hepatitis virus infection.
3.1. The association of Fas-FasL genotype between patients with
and without liver diseases
In HCC group, there were 86 patients with AFP <400 ng/ml, 22
patients with AFP 400 ng/ml, 79 patients with early stage of HCC
(CLIP score 0e1), and 31 patients with late stage HCC (CLIP score
2e6).
The association between patients with HCC or cirrhosis of the
liver and controls was assessed in Table 2. In patients with HCC, the
AA, AG and GG genotype distribution of Fas670 was 26.1, 51.4 and
22.5, respectively, which showed no signiﬁcant difference from the
controls (30.3, 50.0 and 19.7). The AA, AG and GG genotype dis-
tribution of Fas670 in patients with cirrhosis of liver was 23.5, 54.0
and 22.5, respectively, which again was no different than those in
the control group. Similarly, we could not identify any signiﬁcant
difference between patients with HCC or cirrhosis of the liver and
controls in Fas1377 and FasL844.
3.2. The association between viral status and Fas-FasL genotypes in
patients with HCC or cirrhosis
In patients with HCC and HBV infection, the genotype distri-
bution of AA, AG and GG in Fas670 is 25.5, 54.3 and 20.2,Table 1
Demography data of all included patients.
Control HCC Cirrhosis
Gender
M 200 100 106
F 100 42 51
Age (year)
Mean ± SD 59.1 ± 13.2 58.9 ± 13.3 59.3 ± 13.4
Virology status
HBV(þ) 0 100 107
HCV(þ) 0 35 50respectively, which was no different to those in patients with HCC
and HCV infection (25.7,54.3 and 22.9) (Table 3). Therewere not any
differences between patients with HBV and HCV infection in
Fas1377 and FasL844.
In patients with cirrhosis and HBV infection, the GG genotype of
Fas1377 was 28.7%, which was signiﬁcantly higher than those in
patients with HCV infection (16.0%, P¼ 0.04). When comparedwith
the controls, patients with cirrhosis and HCV infection showed
signiﬁcantly lower AA genotype of Fas670 (16.0 vs. 30.3, p¼ 0.0074)
and GG genotype of Fas1377 (16.0 vs. 33.3, p ¼ 0.026). There were
no differences that had been identiﬁed in controls and HCV infec-
tion cirrhosis of FasL844.
3.3. Genetic polymorphisms and CLIP stage in HCC
The association between CLIP stages and genotypes was
assessed in Table 4. The frequencies of CC, TC and TT genotype of
FasL844 in early stage (CLIP 0e1) was 57.0,36.7 and 6.3, respec-
tively, which was signiﬁcantly different from those in patients with
late stage HCC (CLIP 2e6) (35.5, 45.1 and 19.4, respectively,
p ¼ 0.0002). The genotype comparison of Fas670 and Fas1377 in
patients with HCC early and late stage also revealed no differences
(data not shown). When stratiﬁed by the parameters of CLIP stage
system, however, the association between FasL844 genotype and
AFP level was signiﬁcant. The TT genotype frequency of FasL844 in
patients with higher AFP level (400 ng/dL) was signiﬁcantly
higher than those with lower AFP level (<400 ng/dL) (p ¼ 0.0043).
No other differences could be identiﬁed in the other three param-
eters of the CLIP scoring system (data not shown).
3.4. The associations between SNPs and prognosis
In the HCC group, there were 59 patients with early recurrence
(<1 year post operation), and 51 with late recurrence (>1 year post
operation) (data not shown). There were no signiﬁcant differences
between early and late recurrence groups in the distribution of AA,
AG and GG genotypes of Fas670, Fas1377 and the distribution of CC,
TC, and TTof FasL844 (data not shown). The overall 10-year survival
rate between FasL genotype C/C and T/Cþ T/T also demonstrated no
difference. (p ¼ 0.35) (Fig. 1).
4. Discussion
Our results showed an association between the Fas genotype
and HCV-associated cirrhosis of the liver. The FasL genotype was
also associated with CLIP stages of HCC, where AFP is detrimental
associated with polymorphism and the risk of severe cirrhosis with
chronic HCV infection. The major SNPs in the Fas promoter region
were not associated with HCC patients. When factoring in the
clinical parameters of the CLIP staging system, Child classiﬁcation,
tumor numbers, AFP levels and portal invasion for HCC patients,
only patients with AFP level 400 ng/dL had an association with
FasL 844 T/C polymorphyism.
HCV does not kill the cells it infects, but triggers an immune-
mediated inﬂammatory response (hepatitis) that either rapidly
clears the infection or slowly destroys the liver, causing the
development of HCC and cirrhosis. The outcome is largely deter-
mined by the efﬁciency of the antiviral immune response. So the
innate immune response might be expected to inﬂuence the
outcome of infection.4,20
Apoptosis is an active, genetically programmed phenomenon of
cell death characterized by a unique sequence of events, with
morphological features distinct from necrosis.21 Three pathomor-
phologic features are suggestive of increased apoptosis in the liver
of patients with chronic hepatitis C: (1) the presence of shrinkage
Table 2
The comparison of genotype distribution in Fas670, Fas1377 and FasL844 between controls and liver disease, HCC and cirrhosis groups.
Fas670 p Fas1377 p FasL844 p
AA AG GG AA AG GG CC TC TT
Control(300) 30.3 50.0 19.7 ns 16.0 50.7 33.3 ns 50.7 41.5 7.8 ns
Liver Dz(299) 24.6 52.9 22.5 ns 17.4 54.3 28.3 ns 50.9 39.1 10.0 ns
HCC(142) 26.1 51.4 22.5 ns 17.0 52.5 30.5 ns 52.5 38.3 9.2 ns
Cirrhosis(157) 23.5 54.0 22.5 ns 17.6 55.6 26.8 ns 49.7 39.6 10.7 ns
The numbers shown in this table indicate the population percentages. The numbers in the parentheses in the ﬁrst column denote the case number. ns: no signiﬁcant dif-
ference; Liver Dz: liver disease; HCC: hepatocellular carcinoma.
Table 3
The associations of genotype frequency in Fas670, Fas1377 and FasL844 between HCC or cirrhosis groups and controls.
Fas670 p Fas1377 p FasL844 p
AA AG GG AA AG GG CC TC TT
Control 30.3 50.0 19.7 16.0 50.7 33.3 50.7 41.5 7.8
HCC
HBV(þ) 25.5 54.3 20.2 ns 14.9 56.4 28.7 ns 51.6 39.8 8.6 ns
HCV(þ) 25.7 51.4 22.9 ns 17.6 47.1 35.3 ns 51.4 37.2 11.4 ns
Cirrhosis
HBV(þ) 25.5 54.9 19.6 ns 13.9 57.4 28.7 0.04a 51.5 39.6 8.9 ns
HCV(þ) 16.0 60.0 24.0 0.0074b 22.0 62.0 16.0 0.026c 40.8 44.9 14.3 ns
The numbers shown in this table indicate population percentages. a: the comparison of genotype AA and GG in Fas1377 between HBV related cirrhosis and HCV related
cirrhosis; b: the comparison of genotype AA to AG þ GG in Fas670 between control and HCV related cirrhosis; c: the comparison of genotype AA to GG in Fas1377 between
control and HCV related cirrhosis.
Table 4
The association of genotype frequency in FasL844 and characteristics of HCC.
FasL844 p-Value
CC TC TT
CLIP 0e1 (79) 57.0 36.7 6.3
2e6 (31) 35.5 45.1 19.4 0.0014x
Child
A 51.2 41.5 7.3
B 48.3 38.0 13.7
C 63.6 27.3 9.1 0.08
Tumor number
Single 52.2 42.0 5.8 NS
Multiple 50.9 35.8 13.2
AFP
<400 ng/dL 57.2 34.5 8.3 0.0028c
400 ng/dL 36.4 50.0 13.6
PV thrombosis
(þ) 50.0 39.3 10.7 NS
() 52.1 39.4 8.5
The numbers shown in this table indicate population percentages. The numbers in
parentheses in the ﬁrst column denote the case number; x: the comparison of ge-
notype CC to TC þ TT in FasL844 between early and late HCC stage. c : the com-
parison of genotype CC to TCþ TT in FasL844 between higher and lower AFP level in
HCC patients.
Fig. 1. The overall survival curve of FasL844 CC compared with FasL TC þ TT.
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necrosis; (2) the presence of acidophilic bodies; and (3) focal cell
drop out in the liver lobule. Increased expression of Fas, one of the
most important members of the tumor necrosis factor family re-
ceptors and able to act as a transducer for the apoptotic signal to
complete programmed cell death, has been described in chronic
hepatitis C. Hepatic up-regulation of Fas was found to correlate
with more severe inﬂammation and ongoing HCV infection.3,22,23
Fas expressing cells are potential targets of cytotoxic T lym-
phocytes bearing Fas ligand. The interaction between Fas ligand
and its receptor, Fas, induces apoptosis in the target cell. Hepato-
cyte expression of Fas has been shown to be common in chronic
HCV infection suggesting that apoptosis is a frequent occurrence in
this disease.24Active inﬂammation was observed in chronic hepatitis C pa-
tients who had high levels of serum sFas, suggesting that sFas may
serve as a serological indicator of active inﬂammation in chronic
hepatitis C.22,25 Serum sFas levels may be correlated with the de-
gree of inﬂammation in the liver and Fas expression on hepato-
cytes. Because apoptosis of hepatocytes is determined not only by
Fas/sFas expression but also by expression of FasL/soluble form of
FasL, the inducing effect of FasL on CTL might have exceeded the
inhibitory effect of sFas.3,22,25
Nevertheless, correlation between Fas genotype and histo-
pathological activity grade is consistent with a body of data indi-
cating that Fas-mediated hepatocyte apoptosis contributes
signiﬁcantly to the pathology of chronic hepatitis C. In particular,
activity grade in hepatitis C patients has been correlated with both
the level of Fas expression and the extent of apoptosis in
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expression in hepatocytes could therefore alter hepatocyte
apoptosis, and hence affect the activity grade of HCV patients.26
Genetic polymorphyism in the Fas gene may account for some of
the histopathological variability in chronic hepatitis. Hepatitis C is a
viral infection with a highly variable disease course; approximately
20% of infections are resolved spontaneously, and progressive ﬁbrosis
eventually leads to cirrhosis in 20e30% of chronically infected pa-
tients. In contrast, the role of cytokine gene polymorphyisms in HCV
infection is less clear. Of some importance is that the correlation
between Fas -1377G, 690C, 670A haplotype and lower activity
grade was stronger in McIlroy's study.2,26 These results were similar
to our results in that the genotypes of Fas-1377 G/G and Fas-670 A/A
have the lower risk for HCV infected cirrhosis. The data suggests that
the SNPs in the Fas promoter regions strongly correlate to the
severity of cirrhosis caused by HCV infection.
The Fas/FasL system plays an important role in tumor outgrowth
andmetastasis.3,5,14,22e27 FasL expressed in colorectal carcinoma cells
may kill the Fas-positive immune effect of TILs and had a poor
prognosis.12 The expression of FasL on HCC tumor cells is thought to
be a mechanism that tumors employ to escape immune surveil-
lance22,28 and may induce apoptosis of activated T lymphocytes and
had aworse prognosis.27 The SNPs of FasLhave not beenwell-studied
regarding cancer progression, nor have issues of survival and
disease-free survival been addressed. In our study, the genotype of
FasL844 C/C had a higher rate in the early CLIP score cancer stage and
a lower AFP level. It means that the genotype of FasL844 C/C is related
to the progression of HCC. Then, we analyzed the overall survival
rate. Although there was no signiﬁcant difference between patients
with genotype FasL844 C/C and that of T/C þ T/T, but tended to have
longer survival time.We could not determine these patients' survival
rates or DFS by using SNP, but theymay play an important role in this
study and require additional review and comprehension.
The status of Fas and Fas ligand expression can predict recur-
rence of hepatocellular carcinoma. These results suggest that the
evaluation of Fas and Fas ligand expression potentially has a sig-
niﬁcant prognostic value for DFS of HCC patients, in addition to
patient clinical stage, and can be regarded as a new prognostic
marker.25 Our results suggest that for SNPs of Fas/FasL, there were
no signiﬁcant differences in tumor recurrence within 1 year. The
clinical treatment may confound the disease's natural process and
cause difﬁculties of statistical signiﬁcance.
In conclusion, the SNPs of Fas/FasL promoters are not correlated
with long-time survival in HCV virus-related HCC. Fas polymorphy-
isms are related to HCV related cirrhosis. FasL polymorphyisms are
related to the progression of HCC andmay correlate to the serumAFP
level in patients with HCC. In future studies, we need to assemble a
greater number of cases and attempt to identify the relationship
between FasL polymorphyisms and tumor tissue FasL expression.
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